Cargando…

Cost-Effectiveness of Breast Cancer Control Strategies in Central America: The Cases of Costa Rica and Mexico

This paper reports the most cost-effective policy options to support and improve breast cancer control in Costa Rica and Mexico. Total costs and effects of breast cancer interventions were estimated using the health care perspective and WHO-CHOICE methodology. Effects were measured in disability-adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Niëns, Laurens M., Zelle, Sten G., Gutiérrez-Delgado, Cristina, Rivera Peña, Gustavo, Hidalgo Balarezo, Blanca Rosa, Rodriguez Steller, Erick, Rutten, Frans F. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000228/
https://www.ncbi.nlm.nih.gov/pubmed/24769920
http://dx.doi.org/10.1371/journal.pone.0095836
_version_ 1782313601461125120
author Niëns, Laurens M.
Zelle, Sten G.
Gutiérrez-Delgado, Cristina
Rivera Peña, Gustavo
Hidalgo Balarezo, Blanca Rosa
Rodriguez Steller, Erick
Rutten, Frans F. H.
author_facet Niëns, Laurens M.
Zelle, Sten G.
Gutiérrez-Delgado, Cristina
Rivera Peña, Gustavo
Hidalgo Balarezo, Blanca Rosa
Rodriguez Steller, Erick
Rutten, Frans F. H.
author_sort Niëns, Laurens M.
collection PubMed
description This paper reports the most cost-effective policy options to support and improve breast cancer control in Costa Rica and Mexico. Total costs and effects of breast cancer interventions were estimated using the health care perspective and WHO-CHOICE methodology. Effects were measured in disability-adjusted life years (DALYs) averted. Costs were assessed in 2009 United States Dollars (US$). To the extent available, analyses were based on locally obtained data. In Costa Rica, the current strategy of treating breast cancer in stages I to IV at a 80% coverage level seems to be the most cost-effective with an incremental cost-effectiveness ratio (ICER) of US$4,739 per DALY averted. At a coverage level of 95%, biennial clinical breast examination (CBE) screening could improve Costa Rica's population health twofold, and can still be considered very cost-effective (ICER US$5,964/DALY). For Mexico, our results indicate that at 95% coverage a mass-media awareness raising program (MAR) could be the most cost-effective (ICER US$5,021/DALY). If more resources are available in Mexico, biennial mammography screening for women 50–70 yrs (ICER US$12,718/DALY), adding trastuzumab (ICER US$13,994/DALY) or screening women 40–70 yrs biennially plus trastuzumab (ICER US$17,115/DALY) are less cost-effective options. We recommend both Costa Rica and Mexico to engage in MAR, CBE or mammography screening programs, depending on their budget. The results of this study should be interpreted with caution however, as the evidence on the intervention effectiveness is uncertain. Also, these programs require several organizational, budgetary and human resources, and the accessibility of breast cancer diagnostic, referral, treatment and palliative care facilities should be improved simultaneously. A gradual implementation of early detection programs should give the respective Ministries of Health the time to negotiate the required budget, train the required human resources and understand possible socioeconomic barriers.
format Online
Article
Text
id pubmed-4000228
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-40002282014-04-29 Cost-Effectiveness of Breast Cancer Control Strategies in Central America: The Cases of Costa Rica and Mexico Niëns, Laurens M. Zelle, Sten G. Gutiérrez-Delgado, Cristina Rivera Peña, Gustavo Hidalgo Balarezo, Blanca Rosa Rodriguez Steller, Erick Rutten, Frans F. H. PLoS One Research Article This paper reports the most cost-effective policy options to support and improve breast cancer control in Costa Rica and Mexico. Total costs and effects of breast cancer interventions were estimated using the health care perspective and WHO-CHOICE methodology. Effects were measured in disability-adjusted life years (DALYs) averted. Costs were assessed in 2009 United States Dollars (US$). To the extent available, analyses were based on locally obtained data. In Costa Rica, the current strategy of treating breast cancer in stages I to IV at a 80% coverage level seems to be the most cost-effective with an incremental cost-effectiveness ratio (ICER) of US$4,739 per DALY averted. At a coverage level of 95%, biennial clinical breast examination (CBE) screening could improve Costa Rica's population health twofold, and can still be considered very cost-effective (ICER US$5,964/DALY). For Mexico, our results indicate that at 95% coverage a mass-media awareness raising program (MAR) could be the most cost-effective (ICER US$5,021/DALY). If more resources are available in Mexico, biennial mammography screening for women 50–70 yrs (ICER US$12,718/DALY), adding trastuzumab (ICER US$13,994/DALY) or screening women 40–70 yrs biennially plus trastuzumab (ICER US$17,115/DALY) are less cost-effective options. We recommend both Costa Rica and Mexico to engage in MAR, CBE or mammography screening programs, depending on their budget. The results of this study should be interpreted with caution however, as the evidence on the intervention effectiveness is uncertain. Also, these programs require several organizational, budgetary and human resources, and the accessibility of breast cancer diagnostic, referral, treatment and palliative care facilities should be improved simultaneously. A gradual implementation of early detection programs should give the respective Ministries of Health the time to negotiate the required budget, train the required human resources and understand possible socioeconomic barriers. Public Library of Science 2014-04-25 /pmc/articles/PMC4000228/ /pubmed/24769920 http://dx.doi.org/10.1371/journal.pone.0095836 Text en © 2014 Niëns et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Niëns, Laurens M.
Zelle, Sten G.
Gutiérrez-Delgado, Cristina
Rivera Peña, Gustavo
Hidalgo Balarezo, Blanca Rosa
Rodriguez Steller, Erick
Rutten, Frans F. H.
Cost-Effectiveness of Breast Cancer Control Strategies in Central America: The Cases of Costa Rica and Mexico
title Cost-Effectiveness of Breast Cancer Control Strategies in Central America: The Cases of Costa Rica and Mexico
title_full Cost-Effectiveness of Breast Cancer Control Strategies in Central America: The Cases of Costa Rica and Mexico
title_fullStr Cost-Effectiveness of Breast Cancer Control Strategies in Central America: The Cases of Costa Rica and Mexico
title_full_unstemmed Cost-Effectiveness of Breast Cancer Control Strategies in Central America: The Cases of Costa Rica and Mexico
title_short Cost-Effectiveness of Breast Cancer Control Strategies in Central America: The Cases of Costa Rica and Mexico
title_sort cost-effectiveness of breast cancer control strategies in central america: the cases of costa rica and mexico
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000228/
https://www.ncbi.nlm.nih.gov/pubmed/24769920
http://dx.doi.org/10.1371/journal.pone.0095836
work_keys_str_mv AT nienslaurensm costeffectivenessofbreastcancercontrolstrategiesincentralamericathecasesofcostaricaandmexico
AT zellesteng costeffectivenessofbreastcancercontrolstrategiesincentralamericathecasesofcostaricaandmexico
AT gutierrezdelgadocristina costeffectivenessofbreastcancercontrolstrategiesincentralamericathecasesofcostaricaandmexico
AT riverapenagustavo costeffectivenessofbreastcancercontrolstrategiesincentralamericathecasesofcostaricaandmexico
AT hidalgobalarezoblancarosa costeffectivenessofbreastcancercontrolstrategiesincentralamericathecasesofcostaricaandmexico
AT rodriguezstellererick costeffectivenessofbreastcancercontrolstrategiesincentralamericathecasesofcostaricaandmexico
AT ruttenfransfh costeffectivenessofbreastcancercontrolstrategiesincentralamericathecasesofcostaricaandmexico